Robert K. Flamm

Robert K. Flamm's AcademicInfluence.com Rankings

Robert K. Flamm

Biology

#12938

World Rank

#16446

Historical Rank

Microbiology

#787

World Rank

#864

Historical Rank

biology Degrees

Download Badge

Biology

Why Is Robert K. Flamm Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Robert K. Flamm's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Mutations in 23S rRNA are associated with clarithromycin resistance in Helicobacter pylori (1996) (473)
Novel plasmid-mediated beta-lactamase (TEM-10) conferring selective resistance to ceftazidime and aztreonam in clinical isolates of Klebsiella pneumoniae (1989) (202)
Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalized in intensive care units in United States and European hospitals (2009-2011). (2014) (199)
Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalised with pneumonia in US and European hospitals: results from the SENTRY Antimicrobial Surveillance Program, 2009-2012. (2014) (196)
Point mutations in the 23S rRNA gene of Helicobacter pylori associated with different levels of clarithromycin resistance. (1997) (194)
Emergence of macrolide resistance during treatment of pneumococcal pneumonia. (2002) (183)
Antimicrobial Activity of Ceftolozane-Tazobactam Tested against Enterobacteriaceae and Pseudomonas aeruginosa with Various Resistance Patterns Isolated in U.S. Hospitals (2011-2012) (2013) (171)
A PCR-oligonucleotide ligation assay to determine the prevalence of 23S rRNA gene mutations in clarithromycin-resistant Helicobacter pylori (1997) (169)
Prevalence of macrolide resistance mechanisms in Streptococcus pneumoniae isolates from a multicenter antibiotic resistance surveillance study conducted in the United States in 1994-1995. (1999) (162)
Fluoroquinolone Resistance in Streptococcus pneumoniae in United States since 1994-1995 (2002) (154)
Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011-12). (2014) (135)
Meropenem-Vaborbactam Tested against Contemporary Gram-Negative Isolates Collected Worldwide during 2014, Including Carbapenem-Resistant, KPC-Producing, Multidrug-Resistant, and Extensively Drug-Resistant Enterobacteriaceae (2017) (129)
Factors Associated with Relative Rates of Antibiotic Resistance in Pseudomonas aeruginosa Isolates Tested in Clinical Laboratories in the United States from 1999 to 2002 (2004) (127)
Ceftolozane/tazobactam activity tested against Gram-negative bacterial isolates from hospitalised patients with pneumonia in US and European medical centres (2012). (2014) (124)
Novel mechanism of macrolide resistance in Streptococcus pneumoniae. (1996) (119)
Affinity of Doripenem and Comparators to Penicillin-Binding Proteins in Escherichia coli and Pseudomonas aeruginosa (2008) (116)
Antimicrobial susceptibility testing of Helicobacter pylori. Comparison of E-test, broth microdilution, and disk diffusion for ampicillin, clarithromycin, and metronidazole. (1996) (113)
Detection of mcr-1 among Escherichia coli Clinical Isolates Collected Worldwide as Part of the SENTRY Antimicrobial Surveillance Program in 2014 and 2015 (2016) (113)
Antimicrobial Activity of Ceftazidime-Avibactam against Gram-Negative Organisms Collected from U.S. Medical Centers in 2012 (2013) (112)
Characterization and Prevalence of MefA, MefE, and the Associated msr(D) Gene in Streptococcus pneumoniae Clinical Isolates (2004) (111)
Novel erythromycin derivatives with aryl groups tethered to the C-6 position are potent protein synthesis inhibitors and active against multidrug-resistant respiratory pathogens. (2001) (106)
Update of dalbavancin spectrum and potency in the USA: report from the SENTRY Antimicrobial Surveillance Program (2011). (2013) (103)
Hydrolysis and Inhibition Profiles of β-Lactamases from Molecular Classes A to D with Doripenem, Imipenem, and Meropenem (2009) (103)
In Vitro Antibacterial Potency and Spectrum of ABT-492, a New Fluoroquinolone (2003) (103)
Longitudinal survey of carbapenem resistance and resistance mechanisms in Enterobacteriaceae and non-fermenters from the USA in 2007-09. (2011) (96)
Design, synthesis, and antimicrobial activity of 6-O-substituted ketolides active against resistant respiratory tract pathogens. (2000) (94)
Linezolid Surveillance Results for the United States: LEADER Surveillance Program 2011 (2012) (94)
Update on antimicrobial susceptibility trends among Streptococcus pneumoniae in the United States: report of ceftaroline activity from the SENTRY Antimicrobial Surveillance Program (1998-2011). (2013) (93)
Effect of the β-Lactamase Inhibitor Vaborbactam Combined with Meropenem against Serine Carbapenemase-Producing Enterobacteriaceae (2016) (93)
Studies of the Novel Ketolide ABT-773: Transport, Binding to Ribosomes, and Inhibition of Protein Synthesis inStreptococcus pneumoniae (2000) (84)
Pseudomonas aeruginosa Antimicrobial Susceptibility Results from Four Years (2012 to 2015) of the International Network for Optimal Resistance Monitoring Program in the United States (2017) (82)
Antimicrobial Activity of Ceftolozane-Tazobactam Tested Against Enterobacteriaceae and Pseudomonas aeruginosa with Various Resistance Patterns Isolated in U.S. Hospitals (2013-2016) as Part of the Surveillance Program: Program to Assess Ceftolozane-Tazobactam Susceptibility. (2017) (81)
Antimicrobial Activity of Ceftazidime-Avibactam Tested against Multidrug-Resistant Enterobacteriaceae and Pseudomonas aeruginosa Isolates from U.S. Medical Centers, 2013 to 2016 (2017) (81)
Daptomycin activity tested against 164457 bacterial isolates from hospitalised patients: summary of 8 years of a Worldwide Surveillance Programme (2005-2012). (2014) (78)
Multidrug resistance among Acinetobacter spp. in the USA and activity profile of key agents: results from CAPITAL Surveillance 2010. (2012) (78)
Identification of TEM-26 beta-lactamase responsible for a major outbreak of ceftazidime-resistant Klebsiella pneumoniae (1994) (76)
Zyvox® Annual Appraisal of Potency and Spectrum (ZAAPS) program: report of linezolid activity over 9 years (2004-12). (2014) (75)
Ceftolozane/tazobactam activity tested against aerobic Gram-negative organisms isolated from intra-abdominal and urinary tract infections in European and United States hospitals (2012). (2014) (74)
Linezolid Surveillance Results for the United States (LEADER Surveillance Program 2014) (2016) (74)
Comparison of In Vitro Activities of ABT-773 and Telithromycin against Macrolide-Susceptible and -Resistant Streptococci and Staphylococci (2002) (74)
In vitro activity of meropenem/vaborbactam and characterisation of carbapenem resistance mechanisms among carbapenem-resistant Enterobacteriaceae from the 2015 meropenem/vaborbactam surveillance programme. (2018) (74)
Antimicrobial Susceptibility of Enterobacteriaceae and Pseudomonas aeruginosa Isolates from United States Medical Centers Stratified by Infection Type: Results from the International Network for Optimal Resistance Monitoring (INFORM) Surveillance Program, 2015-2016. (2018) (72)
In Vitro and Bactericidal Activities of ABT-492, a Novel Fluoroquinolone, against Gram-Positive and Gram-Negative Organisms (2004) (71)
WCK 5222 (cefepime/zidebactam) antimicrobial activity tested against Gram-negative organisms producing clinically relevant &bgr;-lactamases (2017) (71)
Ceftazidime/avibactam tested against Gram-negative bacteria from intensive care unit (ICU) and non-ICU patients, including those with ventilator-associated pneumonia. (2015) (71)
Ceftazidime-Avibactam Activity against Multidrug-Resistant Pseudomonas aeruginosa Isolated in U.S. Medical Centers in 2012 and 2013 (2015) (69)
Ceftolozane-Tazobactam Activity against Pseudomonas aeruginosa Clinical Isolates from U.S. Hospitals: Report from the PACTS Antimicrobial Surveillance Program, 2012 to 2015 (2017) (68)
In Vitro Activity of Delafloxacin against Contemporary Bacterial Pathogens from the United States and Europe, 2014 (2017) (68)
Use of a surfactant (polysorbate 80) to improve MIC susceptibility testing results for polymyxin B and colistin. (2012) (68)
Summary of Ceftaroline Activity against Pathogens in the United States, 2010: Report from the Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE) Surveillance Program (2012) (64)
Tigecycline activity tested against antimicrobial resistant surveillance subsets of clinical bacteria collected worldwide (2011). (2013) (64)
Synthesis and structure-activity relationships of 2-pyridones: a novel series of potent DNA gyrase inhibitors as antibacterial agents. (1996) (63)
In Vitro Activity of Delafloxacin and Microbiological Response against Fluoroquinolone-Susceptible and Nonsusceptible Staphylococcus aureus Isolates from Two Phase 3 Studies of Acute Bacterial Skin and Skin Structure Infections (2017) (62)
Evolving oxazolidinone resistance mechanisms in a worldwide collection of enterococcal clinical isolates: results from the SENTRY Antimicrobial Surveillance Program (2018) (62)
Ceftobiprole Activity against over 60,000 Clinical Bacterial Pathogens Isolated in Europe, Turkey, and Israel from 2005 to 2010 (2014) (61)
Antimicrobial susceptibility and molecular characterization of community-acquired methicillin-resistant Staphylococcus aureus. (2002) (61)
In Vitro Activity of Plazomicin against Gram-Negative and Gram-Positive Isolates Collected from U.S. Hospitals and Comparative Activities of Aminoglycosides against Carbapenem-Resistant Enterobacteriaceae and Isolates Carrying Carbapenemase Genes (2018) (61)
An international activity and spectrum analysis of linezolid: ZAAPS Program results for 2011. (2013) (61)
Tigecycline activity tested against carbapenem-resistant Enterobacteriaceae from 18 European nations: results from the SENTRY surveillance program (2010-2013). (2015) (61)
Antimicrobial activity of daptomycin tested against Gram-positive pathogens collected in Europe, Latin America, and selected countries in the Asia-Pacific Region (2011). (2013) (61)
Ceftazidime/avibactam activity tested against Gram-negative bacteria isolated from bloodstream, pneumonia, intra-abdominal and urinary tract infections in US medical centres (2012). (2014) (61)
Tight binding of clarithromycin, its 14-(R)-hydroxy metabolite, and erythromycin to Helicobacter pylori ribosomes (1994) (60)
Antimicrobial Activities of Aztreonam-Avibactam and Comparator Agents against Contemporary (2016) Clinical Enterobacteriaceae Isolates (2017) (60)
Surveillance for linezolid resistance via the Zyvox® Annual Appraisal of Potency and Spectrum (ZAAPS) programme (2014): evolving resistance mechanisms with stable susceptibility rates. (2016) (59)
Longitudinal (2001-14) analysis of enterococci and VRE causing invasive infections in European and US hospitals, including a contemporary (2010-13) analysis of oritavancin in vitro potency. (2016) (58)
WCK 5222 (Cefepime-Zidebactam) Antimicrobial Activity against Clinical Isolates of Gram-Negative Bacteria Collected Worldwide in 2015 (2017) (58)
Five-Year Summary of In Vitro Activity and Resistance Mechanisms of Linezolid against Clinically Important Gram-Positive Cocci in the United States from the LEADER Surveillance Program (2011 to 2015) (2017) (56)
Induction of ribosome methylation in MLS-resistant Streptococcus pneumoniae by macrolides and ketolides. (1999) (56)
Temporal and Geographic Variation in Antimicrobial Susceptibility and Resistance Patterns of Enterococci: Results From the SENTRY Antimicrobial Surveillance Program, 1997–2016 (2019) (55)
Synthesis and antimicrobial activity of 4H-4-oxoquinolizine derivatives: consequences of structural modification at the C-8 position. (1999) (54)
LEADER surveillance program results for 2010: an activity and spectrum analysis of linezolid using 6801 clinical isolates from the United States (61 medical centers). (2012) (53)
Activity of plazomicin compared with other aminoglycosides against isolates from European and adjacent countries, including Enterobacteriaceae molecularly characterized for aminoglycoside-modifying enzymes and other resistance mechanisms (2018) (53)
In Vitro Spectrum of Pexiganan Activity When Tested against Pathogens from Diabetic Foot Infections and with Selected Resistance Mechanisms (2015) (51)
Avibactam reverts the ceftazidime MIC90 of European Gram-negative bacterial clinical isolates to the epidemiological cut-off value (2014) (51)
Molecular Epidemiology of Macrolide Resistance in Neonatal Bloodstream Isolates of Group B Streptococci (2003) (50)
Surveillance of Omadacycline Activity Tested against Clinical Isolates from the United States and Europe as Part of the 2016 SENTRY Antimicrobial Surveillance Program (2018) (50)
Pharmacokinetic-Pharmacodynamic-Model-Guided Doripenem Dosing in Critically Ill Patients (2010) (50)
In Vitro Activity of Gepotidacin (GSK2140944) against Neisseria gonorrhoeae (2017) (49)
Surveillance of Omadacycline Activity against Clinical Isolates from a Global Collection (North America, Europe, Latin America, Asia-Western Pacific), 2010-2011 (2017) (49)
In Vitro Activity of APX001A (Manogepix) and Comparator Agents against 1,706 Fungal Isolates Collected during an International Surveillance Program in 2017 (2019) (48)
ZAAPS programme results for 2016: an activity and spectrum analysis of linezolid using clinical isolates from medical centres in 42 countries (2018) (47)
Ceftazidime-avibactam and comparator agents tested against urinary tract isolates from a global surveillance program (2011). (2014) (45)
Antimicrobial Activity of Ceftaroline Tested against Staphylococci with Reduced Susceptibility to Linezolid, Daptomycin, or Vancomycin from U.S. Hospitals, 2008 to 2011 (2013) (45)
Antimicrobial Susceptibility of Streptococcus pneumoniae from North America, Europe, Latin America, and the Asia-Pacific Region: Results From 20 Years of the SENTRY Antimicrobial Surveillance Program (1997–2016) (2019) (45)
Summary of Linezolid Activity and Resistance Mechanisms Detected during the 2012 LEADER Surveillance Program for the United States (2013) (45)
Geographical and temporal variation in the frequency and antimicrobial susceptibility of bacteria isolated from patients hospitalized with bacterial pneumonia: results from 20 years of the SENTRY Antimicrobial Surveillance Program (1997-2016). (2019) (45)
Tigecycline antimicrobial activity tested against clinical bacteria from Latin American medical centres: results from SENTRY Antimicrobial Surveillance Program (2011-2014). (2016) (44)
Comparative activity of carbapenem testing: the COMPACT study. (2011) (44)
Variation in Potency and Spectrum of Tigecycline Activity against Bacterial Strains from U.S. Medical Centers since Its Approval for Clinical Use (2006 to 2012) (2014) (44)
Transport and storage ofHelicobacter pylori from gastric mucosal biopsies and clinical isolates (1995) (43)
Activities of carbapenem and comparator agents against contemporary US Pseudomonas aeruginosa isolates from the CAPITAL surveillance program. (2013) (43)
Gepotidacin (GSK2140944) In Vitro Activity against Gram-Positive and Gram-Negative Bacteria (2017) (43)
Molecular typing of Helicobacter pylori isolates from a multicenter U.S. clinical trial by ureC restriction fragment length polymorphism (1997) (41)
Antimicrobial Activity of Ceftazidime-Avibactam against Gram-Negative Bacteria Isolated from Patients Hospitalized with Pneumonia in U.S. Medical Centers, 2011 to 2015 (2017) (41)
Frequency and antimicrobial susceptibility of Gram-negative bacteria isolated from patients with pneumonia hospitalized in ICUs of US medical centres (2015–17) (2018) (39)
A 1997-1998 national surveillance study: Moraxella catarrhalis and Haemophilus influenzae antimicrobial resistance in 34 US institutions. (1999) (39)
Comparative In Vitro Activity of ABT-773, a Novel Antibacterial Ketolide (2001) (39)
Antimicrobial Activity of Ceftaroline-Avibactam Tested against Clinical Isolates Collected from U.S. Medical Centers in 2010-2011 (2013) (38)
Dalbavancin in-vitro activity obtained against Gram-positive clinical isolates causing bone and joint infections in US and European hospitals (2011-2016). (2017) (38)
In Vitro Activity of Delafloxacin Tested against Isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis (2016) (38)
Antibacterial Activity of Lefamulin against Pathogens Most Commonly Causing Community-Acquired Bacterial Pneumonia: SENTRY Antimicrobial Surveillance Program (2015–2016) (2019) (38)
The synthesis and biological evaluation of a novel series of antimicrobials of the oxazolidinone class. (2002) (38)
Fluoroquinolone resistance in Streptococcus pyogenes. (2003) (37)
Surrogate analysis of vancomycin to predict susceptible categorization of dalbavancin. (2015) (37)
ZAAPS Program results for 2015: an activity and spectrum analysis of linezolid using clinical isolates from medical centres in 32 countries (2017) (36)
Worldwide Experience with the Use of Doripenem against Extended-Spectrum-β-Lactamase-Producing and Ciprofloxacin-Resistant Enterobacteriaceae: Analysis of Six Phase 3 Clinical Studies (2010) (36)
Frequency of occurrence and antimicrobial susceptibility of Gram-negative bacteremia isolates in patients with urinary tract infection: results from United States and European hospitals (2009–2011) (2014) (36)
Anhydrolide macrolides. 1. Synthesis and antibacterial activity of 2,3-anhydro-6-O-methyl 11,12-carbamate erythromycin A analogues. (1998) (35)
Activity analyses of staphylococcal isolates from pediatric, adult, and elderly patients: AWARE Ceftaroline Surveillance Program. (2012) (35)
Surveillance of tigecycline activity tested against clinical isolates from a global (North America, Europe, Latin America and Asia-Pacific) collection (2016). (2018) (35)
Antimicrobial activity of ceftolozane-tazobactam tested against gram-negative contemporary (2015-2017) isolates from hospitalized patients with pneumonia in US medical centers. (2019) (34)
Murepavadin activity tested against contemporary (2016–17) clinical isolates of XDR Pseudomonas aeruginosa (2018) (34)
In Vitro Activity of Lefamulin Tested against Streptococcus pneumoniae with Defined Serotypes, Including Multidrug-Resistant Isolates Causing Lower Respiratory Tract Infections in the United States (2016) (33)
Oritavancin Activity against Staphylococcus aureus Causing Invasive Infections in U.S. and European Hospitals: a 5-Year International Surveillance Program (2014) (33)
Activity of dalbavancin and comparator agents against Gram-positive cocci from clinical infections in the USA and Europe 2015–16 (2018) (32)
Antibacterial activity of BMS-180680, a new catechol-containing monobactam (1997) (32)
In vitro evaluation of ABT-719, a novel DNA gyrase inhibitor (1995) (32)
Activity of oritavancin against Gram-positive clinical isolates responsible for documented skin and soft-tissue infections in European and US hospitals (2010-13). (2015) (32)
Antimicrobial Susceptibility of Pseudomonas aeruginosa to Ceftazidime-Avibactam, Ceftolozane-Tazobactam, Piperacillin-Tazobactam, and Meropenem Stratified by U.S. Census Divisions: Results from the 2017 INFORM Program (2018) (32)
Ceftolozane-tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in Latin America: report from an antimicrobial surveillance program (2013–2015) (2017) (31)
Spectrum and potency of ceftaroline tested against leading pathogens causing skin and soft-tissue infections in Europe (2010). (2013) (31)
3-Keto-11,12-carbazate derivatives of 6-O-methylerythromycin A synthesis and in vitro activity. (1996) (31)
In vitro activity of ceftazidime/avibactam against Gram-negative pathogens isolated from pneumonia in hospitalised patients, including ventilated patients. (2016) (31)
Potentiation Effects of Amikacin and Fosfomycin against Selected Amikacin-Nonsusceptible Gram-Negative Respiratory Tract Pathogens (2014) (30)
Activity of ceftaroline and comparator agents tested against Staphylococcus aureus from patients with bloodstream infections in US medical centres (2009-13). (2015) (30)
In vitro activity of linezolid as assessed through the 2013 LEADER surveillance program. (2015) (30)
Ceftaroline Activity against Bacterial Pathogens Frequently Isolated in U.S. Medical Centers: Results from Five Years of the AWARE Surveillance Program (2015) (30)
Antimicrobial susceptibility patterns of community- and hospital-acquired methicillin-resistant Staphylococcus aureus from United States Hospitals: results from the AWARE Ceftaroline Surveillance Program (2012-2014). (2016) (30)
Molecular β-Lactamase Characterization of Aerobic Gram-Negative Pathogens Recovered from Patients Enrolled in the Ceftazidime-Avibactam Phase 3 Trials for Complicated Intra-abdominal Infections, with Efficacies Analyzed against Susceptible and Resistant Subsets (2017) (29)
Ceftaroline activity against bacterial organisms isolated from acute bacterial skin and skin structure infections in United States medical centers (2009-2011). (2014) (29)
Results from the Solithromycin International Surveillance Program (2014) (2016) (29)
Activities of Tedizolid and Linezolid Determined by the Reference Broth Microdilution Method against 3,032 Gram-Positive Bacterial Isolates Collected in Asia-Pacific, Eastern Europe, and Latin American Countries in 2014 (2016) (29)
Activities of Omadacycline and Comparator Agents against Staphylococcus aureus Isolates from a Surveillance Program Conducted in North America and Europe (2016) (29)
Antimicrobial activity of ceftobiprole and comparator agents when tested against contemporary Gram-positive and -negative organisms collected from Europe (2015). (2018) (28)
Antimicrobial activity of ceftaroline and comparator agents tested against bacterial isolates causing skin and soft tissue infections and community-acquired respiratory tract infections isolated from the Asia-Pacific region and South Africa (2010). (2013) (28)
Surveillance of dalbavancin potency and spectrum in the United States (2012). (2013) (28)
In Vitro Activity of Ceftazidime-Avibactam against Contemporary Pseudomonas aeruginosa Isolates from U.S. Medical Centers by Census Region, 2014 (2016) (28)
Comparison of Broth Microdilution, Agar Dilution, and Etest for Susceptibility Testing of Doripenem against Gram-Negative and Gram-Positive Pathogens (2010) (28)
Antimicrobial Activity of Murepavadin Tested against Clinical Isolates of Pseudomonas aeruginosa from the United States, Europe, and China (2018) (28)
Ceftobiprole Activity against Gram-Positive and -Negative Pathogens Collected from the United States in 2006 and 2016 (2018) (27)
Synthesis and structure-activity relationships of 2-pyridones: II. 8-(Fluoro-substituted pyrrolidinyl)-2-pyridones as antibacterial agents. (1998) (27)
Antimicrobial Susceptibility Trends among Staphylococcus aureus Isolates from U.S. Hospitals: Results from 7 Years of the Ceftaroline (AWARE) Surveillance Program, 2010 to 2016 (2017) (27)
Differential Selection of Single-Step AmpC or Efflux Mutants of Pseudomonas aeruginosa by Using Cefepime, Ceftazidime, or Ceftobiprole (2010) (27)
Determination of Disk Diffusion and MIC Quality Control Guidelines for GSK2140944, a Novel Bacterial Type II Topoisomerase Inhibitor Antimicrobial Agent (2014) (27)
Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa collected from patients with bloodstream infections isolated in United States hospitals (2013-2015) as part of the Program to Assess Ceftolozane-Tazobactam Susceptibility (PACTS) surveillanc (2018) (27)
Activity of Debio1452, a FabI Inhibitor with Potent Activity against Staphylococcus aureus and Coagulase-Negative Staphylococcus spp., Including Multidrug-Resistant Strains (2015) (26)
Telavancin In Vitro Activity against a Collection of Methicillin-Resistant Staphylococcus aureus Isolates, Including Resistant Subsets, from the United States (2015) (26)
Efficacies of ABT-773, a New Ketolide, against Experimental Bacterial Infections (2001) (26)
Activity of omadacycline tested against Streptococcus pneumoniae from a global surveillance program (2014). (2018) (26)
Surveillance of omadacycline activity tested against clinical isolates from the United States and Europe: Results from the SENTRY Antimicrobial Surveillance Programme, 2017. (2019) (26)
Epidemiology of macrolide and/or lincosamide resistant Streptococcus pneumoniae clinical isolates with ribosomal mutations. (2004) (26)
Evaluation of the Bactericidal Activity of Fosfomycin in Combination with Selected Antimicrobial Comparison Agents Tested against Gram-Negative Bacterial Strains by Using Time-Kill Curves (2019) (26)
Comparative activity of ceftobiprole against Gram-positive and Gram-negative isolates from Europe and the Middle East: the CLASS study. (2011) (26)
Cefiderocol MIC quality control ranges in iron-depleted cation-adjusted Mueller-Hinton broth using a CLSI M23-A4 multi-laboratory study design. (2017) (26)
β-Lactamase Characterization of Gram-Negative Pathogens Recovered from Patients Enrolled in the Phase 2 Trials for Ceftazidime-Avibactam: Clinical Efficacies Analyzed against Subsets of Molecularly Characterized Isolates (2015) (25)
Comparison of ceftazidime-avibactam and ceftolozane-tazobactam in vitro activities when tested against gram-negative bacteria isolated from patients hospitalized with pneumonia in United States medical centers (2017-2018). (2019) (25)
Low Prevalence of Gram-Positive Isolates Showing Elevated Lefamulin MIC Results during the SENTRY Surveillance Program for 2015–2016 and Characterization of Resistance Mechanisms (2019) (25)
Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in the Asia-Pacific region (minus China, Australia and New Zealand): report from an Antimicrobial Surveillance Programme (2013-2015). (2017) (25)
Molecular β-lactamase characterization of Gram-negative pathogens recovered from patients enrolled in the ceftazidime-avibactam phase 3 trials (RECAPTURE 1 and 2) for complicated urinary tract infections: Efficacies analysed against susceptible and resistant subsets. (2018) (25)
Polymyxin Susceptibility Testing and Interpretive Breakpoints: Recommendations from the United States Committee on Antimicrobial Susceptibility Testing (USCAST) (2019) (25)
In Vitro Activity of Minocycline against U.S. Isolates of Acinetobacter baumannii-Acinetobacter calcoaceticus Species Complex, Stenotrophomonas maltophilia, and Burkholderia cepacia Complex: Results from the SENTRY Antimicrobial Surveillance Program, 2014 to 2018 (2019) (24)
Ceftazidime-avibactam activity when tested against ceftazidime-nonsusceptible Citrobacter spp., Enterobacter spp., Serratia marcescens, and Pseudomonas aeruginosa from Unites States medical centers (2011-2014). (2015) (24)
Cefditoren pivoxil versus cefpodoxime proxetil for community-acquired pneumonia: results of a multicenter, prospective, randomized, double-blind study. (2002) (24)
Antimicrobial Activity of High-Proportion Cefepime-Tazobactam (WCK 4282) against a Large Number of Gram-Negative Isolates Collected Worldwide in 2014 (2017) (24)
In Vitro Activity of the Novel Lactone Ketolide Nafithromycin (WCK 4873) against Contemporary Clinical Bacteria from a Global Surveillance Program (2017) (24)
Spectrum and potency of ceftaroline tested against leading pathogens causing community-acquired respiratory tract infections in Europe (2010). (2013) (23)
Surveillance of Omadacycline Activity Tested against Clinical Isolates from the United States and Europe: Report from the SENTRY Antimicrobial Surveillance Program, 2016 to 2018 (2020) (23)
Synergistic Activity of Ceftobiprole and Vancomycin in a Rat Model of Infective Endocarditis Caused by Methicillin-Resistant and Glycopeptide-Intermediate Staphylococcus aureus (2012) (22)
Minocycline activity tested against Acinetobacter baumannii complex, Stenotrophomonas maltophilia, and Burkholderia cepacia species complex isolates from a global surveillance program (2013). (2016) (22)
Antimicrobial Activities of Ceftazidime-Avibactam and Comparator Agents against Gram-Negative Organisms Isolated from Patients with Urinary Tract Infections in U.S. Medical Centers, 2012 to 2014 (2016) (22)
Activity of doripenem and comparator beta-lactams against US clinical isolates of Streptococcus pneumoniae with defined mutations in the penicillin-binding domains of pbp1a, pbp2b and pbp2x. (2008) (22)
Amikacin-Fosfomycin at a Five-to-Two Ratio: Characterization of Mutation Rates in Microbial Strains Causing Ventilator-Associated Pneumonia and Interactions with Commonly Used Antibiotics (2014) (22)
Novel 3-deoxy-3-descladinosyl-6-O-methyl erythromycin a analogues. Synthesis and in vitro activity (1997) (21)
Antimicrobial Activity of Ceftaroline Tested against Drug-Resistant Subsets of Streptococcus pneumoniae from U.S. Medical Centers (2014) (21)
Frequency of occurrence and antimicrobial susceptibility of bacteria isolated from patients hospitalized with bloodstream infections in United States medical centers (2015-2017). (2019) (21)
Activity of ceftobiprole against methicillin-resistant Staphylococcus aureus strains with reduced susceptibility to daptomycin, linezolid or vancomycin, and strains with defined SCCmec types. (2014) (21)
Update on dalbavancin activity tested against Gram-positive clinical isolates responsible for documented skin and skin-structure infections in US and European hospitals (2011-13). (2016) (21)
Distribution of main Gram-positive pathogens causing bloodstream infections in United States and European hospitals during the SENTRY Antimicrobial Surveillance Program (2010–2016): concomitant analysis of oritavancin in vitro activity (2018) (21)
Antimicrobial Activity of Dalbavancin against Staphylococcus aureus with Decreased Susceptibility to Glycopeptides, Daptomycin, and/or Linezolid from U.S. Medical Centers (2017) (20)
Efficacy of a New Fluoroquinolone, JNJ-Q2, in Murine Models of Staphylococcus aureus and Streptococcus pneumoniae Skin, Respiratory, and Systemic Infections (2011) (20)
Antimicrobial activity of ceftaroline combined with avibactam tested against bacterial organisms isolated from acute bacterial skin and skin structure infections in United States medical centers (2010-2012). (2014) (20)
In Vivo Activity of Ceftobiprole in Murine Skin Infections Due to Staphylococcus aureus and Pseudomonas aeruginosa (2009) (20)
In vitro Etest synergy of doripenem with amikacin, colistin, and levofloxacin against Pseudomonas aeruginosa with defined carbapenem resistance mechanisms as determined by the Etest method. (2012) (20)
Baseline Activity of Telavancin against Gram-Positive Clinical Isolates Responsible for Documented Infections in U.S. Hospitals (2011-2012) as Determined by the Revised Susceptibility Testing Method (2014) (20)
ZAAPS Program results for 2010: an activity and spectrum analysis of linezolid using clinical isolates from 75 medical centres in 24 countries (2012) (20)
Ceftaroline Activity Tested Against Bacterial Isolates From Pediatric Patients: Results from the Assessing Worldwide Antimicrobial Resistance and Evaluation Program for the United States (2011–2012) (2014) (19)
In Vitro Antibacterial Activity of the Pyrrolopyrazolyl-Substituted Oxazolidinone RWJ-416457 (2006) (19)
Ceftolozane-tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in Australia and New Zealand: Report from an Antimicrobial Surveillance Program (2013-2015). (2017) (18)
Activity of oritavancin tested against uncommonly isolated Gram-positive pathogens responsible for documented infections in hospitals worldwide. (2014) (18)
Ceftaroline activity tested against contemporary Latin American bacterial pathogens (2011) (2014) (18)
Oritavancin in vitro activity against gram-positive organisms from European and United States medical centers: results from the SENTRY Antimicrobial Surveillance Program for 2010-2014. (2018) (18)
Antimicrobial activity of ceftaroline and comparator agents tested against organisms isolated from patients with community-acquired bacterial pneumonia in Europe, Asia, and Latin America. (2018) (18)
Activity of JNJ-Q2, a new fluoroquinolone, tested against contemporary pathogens isolated from patients with community-acquired bacterial pneumonia. (2012) (18)
Susceptibility trends of ceftolozane/tazobactam and comparators when tested against European Gram-negative bacterial surveillance isolates collected during 2012-18. (2020) (18)
Antimicrobial Activity of Cefoperazone-Sulbactam Tested against Gram-Negative Organisms from Europe, Asia-Pacific, and Latin America. (2019) (18)
Antimicrobial Activity of Ceftolozane-Tazobactam Tested against Contemporary (2015-2017) P. aeruginosa Isolates from a Global Surveillance Program. (2020) (17)
PCR-RFLP typing of ureC from Helicobacter pylori isolated from gastric biopsies during a European multi-country clinical trial. (1997) (17)
Antimicrobial Activity Evaluation of Tebipenem (SPR859), an Orally Available Carbapenem, against a Global Set of Enterobacteriaceae Isolates, Including a Challenge Set of Organisms (2019) (17)
Antimicrobial activity of dalbavancin tested against Gram-positive organisms isolated from patients with infective endocarditis in US and European medical centres (2019) (17)
Activity of ceftobiprole against Streptococcus pneumoniae isolates exhibiting high-level resistance to ceftriaxone. (2009) (17)
Ceftaroline potency among 9 US Census regions: report from the 2010 AWARE Program. (2012) (17)
Effect of clavulanic acid on activity of beta-lactam antibiotics in Serratia marcescens isolates producing both a TEM beta-lactamase and a chromosomal cephalosporinase (1991) (17)
Kill kinetics of antimicrobial agents against Helicobacter pylori. (1996) (17)
Antimicrobial activity of ceftaroline and comparator agents when tested against numerous species of coagulase-negative Staphylococcus causing infection in US hospitals. (2016) (17)
Ceftaroline activity against organisms isolated from respiratory tract infections in USA hospitals: results from the AWARE Program, 2009-2011. (2014) (17)
Activity of omadacycline tested against Enterobacteriaceae causing urinary tract infections from a global surveillance program (2014). (2018) (17)
Effects of Ceftobiprole and Oxacillin on mecA Expression in Methicillin-Resistant Staphylococcus aureus Clinical Isolates (2009) (17)
Antimicrobial Activity of Omadacycline Tested against Clinical Bacterial Isolates from Hospitals in Mainland China, Hong Kong, and Taiwan: Results from the SENTRY Antimicrobial Surveillance Program (2013 to 2016) (2019) (17)
Ceftobiprole activity when tested against contemporary bacteria causing bloodstream infections in the United States (2016-2017). (2019) (17)
Comparative Effects of Carbapenems on Bacterial Load and Host Immune Response in a Klebsiella pneumoniae Murine Pneumonia Model (2010) (16)
In vitro activity of doripenem and other carbapenems against contemporary Gram-negative pathogens isolated from hospitalised patients in the Asia-Pacific region: results of the COMPACT Asia-Pacific Study. (2010) (16)
PCR-RFLP typing of ureC from Helicobacter pylori isolated in Argentina from gastric biopsies before and after treatment with clarithromycin (1997) (16)
Macrolide and tetracycline resistance among Moraxella catarrhalis isolates from 2009 to 2011. (2012) (16)
Activity of tedizolid against gram-positive clinical isolates causing infections in Europe and surrounding areas (2014–2015) (2019) (16)
PCR-Oligonucleotide Ligation Assay for Detection of Point Mutations Associated with Quinolone Resistance in Streptococcus pneumoniae (2003) (15)
Educational antimicrobial susceptibility testing as a critical component of microbiology laboratory proficiency programs: American Proficiency Institute results for 2007-2011. (2013) (15)
Antimicrobial activity of ceftaroline tested against bacterial isolates causing respiratory tract and skin and skin structure infections in US medical centers in 2013. (2015) (15)
Telavancin activity in vitro tested against a worldwide collection of Gram-positive clinical isolates (2014). (2017) (15)
Characterization of β-Lactamase Content of Ceftazidime-Resistant Pathogens Recovered during the Pathogen-Directed Phase 3 REPRISE Trial for Ceftazidime-Avibactam: Correlation of Efficacy against β-Lactamase Producers (2019) (15)
In vitro activity of dalbavancin against multidrug-resistant Staphylococcus aureus and streptococci from patients with documented infections in Europe and surrounding regions (2011-2013). (2016) (15)
Analysis of 5-year trends in daptomycin activity tested against Staphylococcus aureus and enterococci from European and US hospitals (2009-2013). (2015) (15)
In Vitro Activity of A-192411.29, a Novel Antifungal Lipopeptide (2000) (14)
Antimicrobial Activities of Ceftaroline and Comparator Agents against Bacterial Organisms Causing Bacteremia in Patients with Skin and Skin Structure Infections in U.S. Medical Centers, 2008 to 2014 (2016) (14)
Update on Linezolid In Vitro Activity through the Zyvox Annual Appraisal of Potency and Spectrum Program, 2013 (2015) (14)
Multicenter Investigation of Gepotidacin (GSK2140944) Agar Dilution Quality Control Determinations for Neisseria gonorrhoeae ATCC 49226 (2016) (14)
Ceftazidime–Avibactam Antimicrobial Activity and Spectrum When Tested Against Gram-negative Organisms From Pediatric Patients: Results From the INFORM Surveillance Program (United States, 2011–2015) (2017) (14)
Antimicrobial Activity of Ceftaroline Tested against Staphylococcus aureus from Surgical Skin and Skin Structure Infections in US Medical Centers. (2016) (13)
Activity of telavancin against Gram-positive pathogens isolated from bone and joint infections in North American, Latin American, European and Asia-Pacific nations. (2017) (13)
Molecular Typing of Helicobacter pylori Isolates from a Multicenter U.S. Clinical Trial by ureC Restriction Fragment Length Polymorphism (1998) (13)
Activity of fosfomycin when tested against US contemporary bacterial isolates. (2019) (13)
Daptomycin Activity against Uncommonly Isolated Streptococcal and Other Gram-Positive Species Groups (2013) (13)
Ceftazidime-Avibactam Activity against Aerobic Gram Negative Organisms Isolated from Intra-Abdominal Infections in United States Hospitals, 2012-2014. (2016) (13)
Activity of ceftolozane-tazobactam and comparators when tested against Gram-negative isolates collected from paediatric patients in the USA and Europe between 2012 and 2016 as part of a global surveillance programme. (2019) (13)
Ceftaroline Activity Against Multidrug-Resistant Streptococcus pneumoniae from U.S. Medical Centers (2014) and Molecular Characterization of a Single Ceftaroline Nonsusceptible Isolate. (2017) (13)
Ceftaroline Activity Tested against Bacterial Isolates Causing Community-Acquired Respiratory Tract Infections and Skin and Skin Structure Infections in Pediatric Patients from United States Hospitals: 2012-2014. (2017) (13)
Dilution Factor of Quantitative Bacterial Cultures Obtained by Bronchoalveolar Lavage in Patients with Ventilator-Associated Bacterial Pneumonia (2017) (12)
Tedizolid in vitro activity against Gram-positive clinical isolates causing bone and joint infections in hospitals in the USA and Europe (2014-17). (2019) (12)
In Vitro Activities of Ceftaroline and Comparators against Streptococcus pneumoniae Isolates from U.S. Hospitals: Results from Seven Years of the AWARE Surveillance Program (2010 to 2016) (2017) (12)
Antimicrobial Activity of First-in-Class Antifungal, Manogepix, and Comparator Agents Testing against Contemporary Invasive Fungal Isolates from an International Surveillance Program (2018-2019): In Vitro Activity of Manogepix against Fungal Isolates. (2021) (12)
In vitro spectrum of pexiganan activity; bactericidal action and resistance selection tested against pathogens with elevated MIC values to topical agents. (2016) (11)
Comparison of emm Typing and Ribotyping with Three Restriction Enzymes To Characterize Clinical Isolates of Streptococcus pyogenes (2005) (11)
Assessment of Tedizolid In Vitro Activity and Resistance Mechanisms against a Collection of Enterococcus spp. Causing Invasive Infections, Including Isolates Requiring an Optimized Dosing Strategy for Daptomycin from U.S. and European Medical Centers, 2016 to 2018 (2020) (11)
Oritavancin in vitro activity against contemporary Staphylococcus aureus isolates responsible for invasive community- and healthcare-associated infections among patients in the United States (2013-2014). (2016) (10)
Interim susceptibility testing for ceftaroline, a new MRSA-active cephalosporin: selecting potent surrogate β-lactam markers to predict ceftaroline activity against clinically indicated species. (2013) (10)
Presence of Macrolide Resistance in Respiratory Flora of HIV-Infected Patients Receiving Either Clarithromycin or Azithromycin for Mycobacterium avium Complex Prophylaxis (2001) (10)
Surveillance of JNJ-Q2 activity tested against Staphylococcus aureus and beta-hemolytic streptococci as a component of the 2010 SENTRY Antimicrobial Surveillance Program. (2011) (10)
Mutations in 23S rRNA are associated with clarithromycin resistance in H. pylori (1996) (10)
Development of Broth Microdilution MIC and Disk Diffusion Antimicrobial Susceptibility Test Quality Control Ranges for the Combination of Cefepime and the Novel β-Lactamase Inhibitor Enmetazobactam (2019) (10)
Evaluation of Antimicrobial Effects of a New Polymyxin Molecule (SPR741) When Tested in Combination with a Series of β-Lactam Agents Against a Challenge Set of Gram-Negative Pathogens. (2020) (10)
Telavancin activity tested against Gram-positive clinical isolates from European, Russian and Israeli hospitals (2011–2013) using a revised broth microdilution testing method: redefining the baseline activity of telavancin (2016) (9)
Ceftaroline activity tested against uncommonly isolated Gram-positive pathogens: report from the SENTRY Antimicrobial Surveillance Program (2008-2011). (2014) (9)
Activity of dalbavancin tested against Gram-positive clinical isolates causing skin and skin-structure infections in paediatric patients from US hospitals (2014-2015). (2017) (9)
2562. Re-Appraisal of Aminoglycoside (AG) Susceptibility Testing Breakpoints Based on the Application of Pharmacokinetics–Pharmacodynamics (PK-PD) and Contemporary Microbiology Surveillance Data (2018) (9)
In Vitro Activity of Telavancin Against Clinically Important Gram-Positive Pathogens from 69 U.S. Medical Centers (2015): Potency Analysis by U.S. Census Divisions (2017) (9)
Ceftobiprole Activity against Bacteria from Skin and Skin Structure Infections in the United States from 2016 through 2018 (2020) (9)
Determination of MIC and disk diffusion quality control guidelines for meropenem-vaborbactam, a novel carbapenem/boronic acid β-lactamase inhibitor combination. (2017) (9)
In Vitro Activity of KBP-7072, a Novel Third-Generation Tetracycline, against 531 Recent Geographically Diverse and Molecularly Characterized Acinetobacter baumannii Species Complex Isolates (2020) (9)
Variability in susceptibilities of Haemophilus influenzae to clarithromycin and azithromycin due to medium pH (1997) (9)
In Vitro Activity of Tedizolid in Comparison with Other Oral and Intravenous Agents Against a Collection of Community-Acquired Methicillin-Resistant Staphylococcus aureus (2014-2015) in the United States. (2019) (9)
Ribosome affinity and the prolonged molecular postantibiotic effect of cethromycin (ABT-773) in Haemophilus influenzae. (2004) (9)
Prevalence of macrolide-lincosamide resistance and multidrug resistance phenotypes in streptococcal isolates causing infections in European hospitals: Evaluation of the in vitro activity of oritavancin and comparator agents. (2017) (8)
A survey of clinical isolates of Enterobacteriaceae using a series of DNA probes for aminoglycoside resistance genes. (1993) (8)
Antimicrobial Resistance Surveillance and New Drug Development (2019) (8)
Assessment of 30/20-Microgram Disk Content versus MIC Results for Ceftazidime-Avibactam Tested against Enterobacteriaceae and Pseudomonas aeruginosa (2018) (8)
Analysis of Vancomycin Susceptibility Testing Results for Presumptive Categorization of Telavancin (2015) (7)
Comparison of the In Vitro Susceptibility of Ceftolozane-Tazobactam With the Cumulative Susceptibility Rates of Standard Antibiotic Combinations When Tested Against Pseudomonas aeruginosa From ICU Patients With Bloodstream Infections or Pneumonia (2019) (7)
Ceftaroline Activity Tested Against Bacterial Isolates Causing Community-acquired Respiratory Tract Infections and Skin and Skin Structure Infections in Pediatric Patients From United States Hospitals: 2012-2014. (2017) (7)
Evaluation of the Revised Ceftaroline Disk Diffusion Breakpoints When Testing a Challenge Collection of Methicillin-Resistant Staphylococcus aureus Isolates (2018) (7)
Determination of Disk Diffusion and MIC Quality Control Guidelines for Solithromycin, a Novel Fluoroketolide Antibacterial, against Neisseria gonorrhoeae (2015) (7)
Telavancin activity tested against a collection of Staphylococcus aureus isolates causing pneumonia in hospitalized patients in the United States (2013-2014). (2016) (7)
Antimicrobial Activity of Ceftazidime-Avibactam Tested against Multidrug-Resistant Enterobacteriaceae and Pseudomonas aeruginosa Isolates from United States (US) Medical Centers (2013–2016) (2017) (7)
In Vitro Activity of RX-P873 against Enterobacteriaceae, Pseudomonas aeruginosa, and Acinetobacter baumannii (2015) (7)
In vitro activity of ceftaroline tested against isolates from the Asia-Pacific region and South Africa (2011). (2014) (6)
In Vitro Activity of Delafloxacin and Microbiological Response Against Fluoroquinolone Susceptible and Non-Susceptible S. aureus Isolates from Two Phase 3 Studies of Acute Bacterial Skin and Skin Structure Infections (ABSSSIs) (2016) (6)
Surveillance of omadacycline activity tested against clinical isolates from the United States: Report from the SENTRY Antimicrobial Surveillance Program, 2019: Omadacycline 2019 Surveillance - USA. (2021) (6)
Genotypic Characterization of Methicillin-Resistant Staphylococcus aureus Recovered at Baseline from Phase 3 Pneumonia Clinical Trials for Ceftobiprole (2016) (6)
Antimicrobial Activity of Telavancin Tested In Vitro Against a Global Collection of Gram-Positive Pathogens, Including Multidrug-Resistant Isolates (2015-2017). (2020) (5)
1363. Sulopenem Activity Against Enterobacteriaceae Isolates From Patients With Urinary Tract Infection or Intra-Abdominal Infection (2018) (5)
Comparison of minimum inhibitory concentration results for gepotidacin obtained using agar dilution and broth microdilution methods. (2020) (5)
Delafloxacin In Vitro Broth Microdilution and Disk Diffusion Antimicrobial Susceptibility Testing Guidelines: Susceptibility Breakpoint Criteria and Quality Control Ranges for an Expanded-Spectrum Anionic Fluoroquinolone (2018) (5)
Comparison of selection for mutants with reduced susceptibility to ABT-773, erythromycin and rifampicin in respiratory tract pathogens. (2002) (5)
Activity of Plazomicin against Enterobacteriaceae Isolates Collected in the United States Including Isolates Carrying Aminoglycoside-Modifying Enzymes Detected by Whole Genome Sequencing (2017) (5)
Affinity of Ceftobiprole for Penicillin-Binding Protein 2b in Streptococcus pneumoniae Strains with Various Susceptibilities to Penicillin (2010) (5)
Spectrum and potency of ceftaroline against leading pathogens causing community-acquired respiratory tract and skin and soft tissue infections in Latin America, 2010 (2013) (5)
The new antibacterial class: The ketolides (2000) (5)
Ceftaroline activity tested against viridans group streptococci from US hospitals. (2016) (5)
More potency assay results for generic non-USA lots of piperacillin/tazobactam and initial reports for generic meropenem compounds marketed in the USA. (2013) (5)
Old In Vitro Antimicrobial Breakpoints Are Misleading Stewardship Efforts, Delaying Adoption of Innovative Therapies, and Harming Patients (2020) (4)
Antimicrobial activity of POL7306 tested against clinical isolates of Gram-negative bacteria collected worldwide. (2020) (4)
Update on the activity of delafloxacin on acute bacterial skin and skin structure infection isolates from European hospitals (2014-2019). (2020) (4)
Regional Analysis of Telavancin and Comparator Antimicrobial Activity against Multidrug-Resistant Staphylococcus aureus Collected in the United States from 2014 through 2016. (2020) (4)
The application of in vitro surveillance data for antibacterial dose selection (2017) (4)
Comparative potencies of contemporary generic vancomycin lot: in vitro assay results from nine products and a reference reagent-grade sample. (2013) (4)
Comparative In Vitro Activities of New Antibiotics for the Treatment of Skin Infections (2019) (4)
Activity of Delafloxacin When Tested Against Bacterial Surveillance Isolates Collected in the US and Europe During 2014–2016 as Part of a Global Surveillance Program (2017) (4)
In Vitro Evaluation of Delafloxacin Activity when Tested Against Contemporary community-Acquired Bacterial Respiratory Tract Infection Isolates (2014–2016): Results from the Sentry Antimicrobial Surveillance Program (2017) (4)
Erratum for Pfaller et al., “In Vitro Activity of Delafloxacin against Contemporary Bacterial Pathogens from the United States and Europe, 2014” (2018) (4)
In Vitro Activity of Lefamulin Against a Global Collection of Bacterial Pathogens Commonly Causing Community-Acquired Bacterial Pneumonia (CABP, SENTRY 2015) (2017) (3)
Ceftobiprole Activity When Tested Against Contemporary Bacteria Causing Bloodstream Infections in the US (2016) (2017) (3)
In Vitro activity of Fosfomycin (ZTI-01, Fosfomycin for Injection) Against Contemporary Gram-negative and Gram-positive Isolates- a Comparison of Inter-Method Testing (2016) (3)
In Vitro Activity of Lefamulin against S. aureus Collected Worldwide from Hospitalized Patients with Bacterial Pneumonia (2017) (3)
Telavancin activity when tested by a revised susceptibility testing method against uncommonly isolated Gram-positive pathogens responsible for documented infections in hospitals worldwide (2011-2013). (2015) (3)
Initial Broth Microdilution Quality Control Guidelines for Debio 1452, a FabI Inhibitor Antimicrobial Agent (2015) (3)
Antimicrobial activity of ceftazidime-avibactam and comparator agents when tested against bacterial isolates causing infection in cancer patients (2013-2014). (2017) (3)
Susceptibility trends of ceftolozane/tazobactam and comparators when tested against U.S. gram-negative bacterial surveillance isolates (2012-2018). (2020) (3)
Omadacycline invitro activity against a molecularly characterized collection of clinical isolates with known acquired tetracycline resistance mechanisms. (2020) (3)
3-Keto-11,12-carbazate Derivatives of 6-O-Methylerythromycin A. Synthesis and in vitro Activity (1996) (3)
Program 2011 United States: LEADER Surveillance Linezolid Surveillance Results for the (2014) (3)
Antimicrobial Activity of Ceftolozane–Tazobactam Tested against Contemporary (2012–2016) Enterobacteriaceae and Pseudomonas aeruginosa Isolates by US Census Division (2017) (3)
In Vitro Antibacterial Activity of Meropenem/RPX7009, (a Carbapenem/â-lactamase Inhibitor Combination) against Contemporary Enterobacteriaceae (ENT) Isolated from Intra-abdominal (IAI) and Urinary Tract Infections (UTI) in the United States (USA) (2015) (3)
Activity of Plazomicin and Comparator Agents Tested Against Gram-negative and -positive Clinical Isolates Collected in USA Hospitals During 2015 (2016) (2)
The Activity of Tedizolid against Gram-positive Pathogens Isolated From Patients in USA Medical Centers: 2014 Surveillance (2015) (2)
Population Pharmacokinetic (PPK) and Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses for Delafloxacin to Support Dose Selection for the Treatment of Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI) (2017) (2)
Oritavancin Activity Tested against Molecularly Characterized Staphylococci and Enterococci Displaying Elevated Linezolid MIC Results (2016) (2)
Analysis of Oritavancin Activity against Gram-Positive Clinical Isolates Responsible for Bacterial Endocarditis in United States and European Hospitals (2008–2016) (2017) (2)
Antimicrobial activity of oritavancin and comparator agents when tested against Gram-positive bacterial isolates causing infections in cancer patients (2014–16) (2018) (2)
1377. Omadacycline In Vitro Activity Against a Molecularly Characterized Collection of Clinical Isolates with Known Tetracycline Resistance Mechanisms (2018) (2)
In vitro activity of KHP-3757 (a novel LpxC inhibitor) and comparator agents against recent and molecularly characterized Pseudomonas aeruginosa isolates from a global surveillance program (2017-2018). (2020) (2)
β-lactamase Characterization of Baseline Enterobacteriaceae (ENT) from a Phase 3 Trial of ceftazidime-avibactam (CAZ-AVI) for the Treatment of Infections Caused by CAZ-nonsusceptible (NS) Pathogens (2015) (2)
Anhydrolide macrolides. 2. Synthesis and antibacterial activity of 2,3-anhydro-6-O-methyl 11,12-carbazate erythromycin A analogues. (1998) (2)
1582. Delafloxacin Activity Against Drug-Resistant Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, and Moraxella catarrhalis from US Medical Centers (2014–2018) (2019) (2)
β-lactamase Characterization of Baseline Pseudomonas aeruginosa (PSA) from Five Ceftazidime-avibactam (CAZ-AVI) Phase 3 Clinical Trials (2017) (2)
Activity of Pexiganan when Tested Against Contemporary Gram-positive and Gram-negative Bacteria Collected from North America, Europe and Japan (2016) (2)
Activity of Meropenem-Vaborbactam Against Enterobacteriaceae Isolates Carrying blaKPC Collected Worldwide (2017) (2)
Determination of Disk Diffusion and MIC Quality Control Guidelines for High-Dose Cefepime-Tazobactam (WCK 4282), a Novel Antibacterial Combination Consisting of a β-Lactamase Inhibitor and a Fourth-Generation Cephalosporin (2017) (2)
246Frequency of Occurrence and Antimicrobial Susceptibility of Gram-negative Organisms Isolated from Health Care–Associated (HCA) Urinary Tract Infections (UTI) in the United States: Results from the Program to Assess Ceftolozane/Tazobactam Susceptibility (PACTS) (2014) (2)
1589. Ceftolozane–Tazobactam Activity Against Difficult-to-Treat Resistance in Pseudomonas aeruginosa from Bloodstream Infections in US Hospitals (2019) (2)
The effect of pulmonary surfactant on the in vitro activity of Iclaprim against common respiratory bacterial pathogens. (2018) (2)
Antimicrobial Activity of Aztreonam-Avibactam and Comparator Agents Tested against Contemporary (2016) Clinical Enterobacteriaceae Isolates (2017) (2)
1365. In Vitro Activity of Lefamulin (LEF) Against Bacterial Pathogens Causing Community-Acquired Bacterial Pneumonia (CABP): SENTRY Surveillance 2016 Results From Asia-Pacific (APAC) and Latin America (LA) (2018) (1)
P2026 Activity of ceftobiprole against Pseudomonas aeruginosa clinical isolates from Europe collected in 2005–2006 (2007) (1)
Cefepime-Zidebactam (WCK 5222) Activity Tested against Gram-negative Organisms Causing Bloodstream Infections Worldwide (2017) (1)
Activity of ceftolozane-tazobactam and comparators when tested against bacterial surveillance isolates collected from patients at risk of infections caused by resistant gram-negative pathogens. (2020) (1)
1364. Efficacy of Omadacycline Against Molecularly Characterized Gram-Positive and Gram-Negative Pathogens Causing Infections in the Phase 3 CABP and ABSSSI Clinical Trials (2018) (1)
Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses for Delafloxacin to Provide Dose Selection Support for the Treatment of Patients with Community-Acquired Bacterial Pneumonia (CABP) (2016) (1)
1523. Antimicrobial Activity of Ceftazidime–Avibactam and Comparator Agents Tested Against Gram-Negative Organisms Isolated from Complicated Urinary Tract Infections: Results from the International Network for Optimal Resistance Monitoring (INFORM) Program (2015) (1)
Telavancin Activity Against Uncommonly Isolated Gram-Positive Pathogens Responsible for Documented Infections in Hospitals Worldwide (2011@2013) When Using A Revised Susceptibility Testing Method (2014) (1)
1260. Activity of Manogepix (APX001A) against 2,669 Fungal Isolates from the SENTRY Surveillance Program (2018-2019) Stratified by Infection Type (2020) (1)
1584. Minocycline Activity Against Stenotrophomonas maltophilia Isolated From Patients in US Hospitals (2019) (1)
Ceftobiprole activity against Gram-positive and Gram-negative pathogens causing bone and joint infections in the United States from 2016 to 2020. (2022) (1)
Antimicrobial Activity of Dalbavancin Tested against Staphylococcus aureus with Decreased Susceptibility to Glycopeptides, Daptomycin, and/or Linezolid from United States (US) Medical Centers (2017) (1)
In vitro activity of omadacycline and comparators against staphylococci, streptococci and enterococci (including resistant organism subsets) from patients in European medical centres during 2016: results from the SENTRY antimicrobial surveillance programme (2017) (1)
2214. Comparison of Cefepime–Zidebactam (WCK 5222), Ceftazidime–Avibactam, and Ceftolozane–Tazobactam Tested Against Gram-Negative Organisms Causing Pneumonia in United States Hospitals in 2018 (2019) (1)
1353. In Vitro Activity of Lefamulin (LEF) Against Bacterial Pathogens Commonly Causing Community-Acquired Bacterial Pneumonia (CABP): 2016 SENTRY Data From the United States (2018) (1)
Dalbavancin I n Vitro Activity Obtained Against Gram-positive Clinical Isolates Causing Osteomyelitis in USA Hospitals (2011 - 2015) (2016) (1)
1463. Activity of Delafloxacin against Multi-Drug-Resistant Fastidious Respiratory Pathogens from European Medical Centers (2014-2019) (2020) (1)
In Vitro Activity of Omadacycline and Comparator Compounds Against Gram-positive Isolates Collected in the USA During 2016 as Part of a Global Surveillance Program (2017) (1)
Erratum for Drusano et al., “Dilution Factor of Quantitative Bacterial Cultures Obtained by Bronchoalveolar Lavage in Patients with Ventilator-Associated Bacterial Pneumonia” (2018) (1)
1345. Comparative Activity of Plazomicin and Other Aminoglycosides Against Enterobacteriaceae Isolates From Various Infection Sources From Hospitalized Patients in the United States (2018) (1)
2427. Comparison of Ceftazidime–Avibactam and Ceftolozane-Tazobactam In Vitro Activities When Tested Against Gram-Negative Bacteria Isolated From Patients Hospitalized With Pneumonia in US Medical Centers (2017) (2018) (1)
P0093 Plazomicin activity against Enterobacteriaceae collected from Europe, Latin America, and Asia-Pacific during 2016, including those with aminoglycoside and beta- lactam resistance mechanisms (2018) (1)
Report of Linezolid Activity from the Linezolid Experience and Accurate Determination of Resistance (LEADER) Program for 2014: Monitoring Resistance Trends and Mechanisms (2015) (1)
470Oritavancin Activity Against Gram-positive Clinical Isolates Responsible for Documented Skin and Skin Structure Infections in USA and European Hospitals (2012-2013) (2014) (1)
Activity Of Ceftolozane/Tazobactam and Comparators Tested Against Carbapenem Non-Susceptible Pseudomonas Aeruginosa Isolates from USA Hospitals (2016) (1)
2192. Comparative Antimicrobial Susceptibility of Gram-Negative Bacteria Isolated from Patients with Bloodstream Infections and Pneumonia when Tested against Tazobactam Combinations (2019) (1)
Multidrug-Resistant Streptococcus pneumoniae (MDRSP) in U.S. Adult Patients: A 2003 Local Perspective (2004) (0)
Antimicrobial Susceptibility of KPC-producing Enterobacteriaceae Stratified by Infection Site (USA, 2012-2015) (2016) (0)
Activity of Tedizolid against Gram-Positive Clinical Isolates Causing Nosocomial- and Community-Acquired Infections in United States Hospitals (2014–2016) (2017) (0)
Prevalence of Main Gram-Positive Pathogens Causing Bloodstream Infections in United States Medical Centers (2010–2015) and Analysis of Oritavancin In Vitro Activity (2016) (0)
1595. Ceftobiprole Activity against Gram-Positive Pathogens Causing Bone and Joint Infections in the United States from 2016 through 2019 (2020) (0)
Yearly Trends of Antimicrobial Non-susceptibility among Streptococcus pneumoniae Serotypes Causing Infections in Adult Patients in the United States (2009–2015) (2017) (0)
Ceftolozane/Tazobactam Activity Tested Against Bacterial Bloodstream Isolates From Multiple Infection Sources (2016) (0)
650: CEFTAZIDIME/AVIBACTAM ACTIVITY AGAINST PSEUDOMONAS AERUGINOSA FROM ICU AND NON-ICU PATIENTS (2016) (0)
Antimicrobial Activity of High-proportion Cefepime-tazobactam (WCK 4282) When Tested against a Large Worldwide Collection of Gram-negative Organisms (2014) (2017) (0)
Antimicrobial Activity of Ceftolozane–Tazobactam Tested against Contemporary (2012–2016) Enterobacteriaceae and Pseudomonas aeruginosa from ICU vs. non-ICU Isolates Collected in US Medical Centers (2017) (0)
1534. Polymyxin Antimicrobial Susceptibility (AST) Testing and Breakpoints for P. aeruginosa, A. baumannii, and Enterobacteriaceae: Recommendations from the United States Committee on Antimicrobial Susceptibility Testing (USCAST) (2019) (0)
1081. Antimicrobial Activity of Dalbavancin Tested Against Gram-Positive Organisms Isolated From Patients With Infective Endocarditis in United States and European Medical Centers (2018) (0)
Comparative Evaluation of the Antimicrobial Susceptibility Patterns of Community- and Hospital-Acquired Methicillin-Resistant S. aureus (MRSA) from USA Hospitals by Site of Infection: Results from the Ceftaroline Surveillance Program AWARE (2012-2014) (2015) (0)
Afﬁnity of Doripenem and Comparators to Penicillin-Binding Proteins in Escherichia coli and Pseudomonas aeruginosa (cid:1) (2008) (0)
Serotype Distributions and Analysis of Susceptibility Profiles of Streptococcus pneumoniae Causing Infections in Adult Patients in the United States (2009-2013) (2016) (0)
Broad In Vitro Activity Analysis of Tedizolid Compared with Other Agents against a Global Collection of Gram-Positive Isolates Causing Bloodstream Infections (2014–2016) (2017) (0)
1444. Trends in Antimicrobial Non-susceptibility of PCV13-Type Streptococcus pneumoniae Pneumonia in Adults in the United States During 2009–2017 (2018) (0)
601: CEFTOLOZANE-TAZOBACTAM ACTIVITY VERSUS RESISTANT PSEUDOMONAS AERUGINOSA FROM PNEUMONIA IN THE U.S. (2020) (0)
1485. Antimicrobial Activity of Ceftolozane-Tazobactam Tested Against Contemporary (2015–2017) Gram-Negative Isolates from Patients with Pneumonia in US Medical Centers (2018) (0)
Antimicrobial Activity of Ceftazidime-Avibactam Tested Against Pseudomonas aeruginosa Isolates from US Hospitals Stratified by Site of Infection: Results From the INFORM Surveillance Program, 2013–2015 (2016) (0)
P68 Ceftazidime–avibactam activity tested against Gram-negative bacterial pathogens in the Asia-Pacific region and South Africa (2010) (2013) (0)
1591. Updated Fluoroquinolone MIC Breakpoints: Impact on Susceptibility Rates in the United States (2019) (0)
In vitro activity of telavancin against Staphylococcus aureus causing pneumonia or skin and skin structure infections with concomitant bloodstream infections in United States hospitals (2012-2016). (2019) (0)
1004. Frequency of Occurrence and Antimicrobial Susceptibility of Bacteria Isolated From Patients Hospitalized With Bloodstream Infections in United States Medical Centers (2015–2017) (2018) (0)
Activity of Omadacycline When Tested Against Gram-Positive Bacteria Isolated From Patients in the United States During 2015 as Part of a Global Surveillance Program. (2016) (0)
247Antimicrobial Activity of Ceftolozane/Tazobactam Tested against Gram-negative Bacterial Isolates from Hospitalized Patients with Pneumonia in United States Hospitals (2013) (2014) (0)
Differential Selection of Single-Step AmpC or Efﬂux Mutants of Pseudomonas aeruginosa by Using Cefepime, Ceftazidime, or Ceftobiprole (cid:1) and Chemo-therapy, (2010) (0)
116: CEFTAZIDIME-AVIBACTAM TESTED AGAINST GRAMNEGATIVE BACTERIA FROM INTENSIVE CARE UNIT (ICU) PATIENTS (2014) (0)
Regional Analysis of Resistance Phenotypes among Staphylococcus aureus Causing Infections in US Census Divisions: Telavancin Activity against Resistant Pathogens (2014-2016) (2017) (0)
In vitro activity of Iclaprim and comparator agents against Listeria monocytogenes clinical isolates from 2012-2018. (2021) (0)
Activity of Linezolid when Tested against Gram-Positive Isolates from the USA (Linezolid Experience and Accurate Determination of Resistance [LEADER]) from 2015 (2016) (0)
1620. Minocycline Activity Against Unusual Clinically Significant Gram-Negative Pathogens (2020) (0)
Arbekacin Tested against Well Characterized Multidrug-Resistant (MDR) Gram-negative Bacilli and Methicillin-Resistant Staphylococcus aureus (MRSA) (2014) (0)
811Antimicrobial activity of ceftaroline tested against respiratory tract infection (RTI) pathogens isolated from USA medical centers in 2013 (2014) (0)
Activity of Dalbavancin Tested Against Gram-positive Clinical Isolates Causing Skin and Skin Structure Infections in Pediatric Patients from USA Hospitals (2014 - 2015). (2016) (0)
471Antimicrobial Activity and Spectrum of Ceftaroline Tested Against Bacterial Isolates Causing Skin and Skin Structure Infections (SSSI) in United States (USA) Medical Centers (2014) (0)
2373. Evaluation of Delafloxacin Activity and Treatment Outcome for Phase 3 Acute Bacterial Skin and Skin Structure Infection Clinical Trial Anaerobic Isolates (2018) (0)
Antimicrobial Susceptibility of Pseudomonas aeruginosa: Results from Four years (2012-2015) of the International Network for Optimal Resistance Monitoring (INFORM) Program in the United States (2017) (0)
Analysis of Telavancin in vitro Activity Tested Against a USA Collection of Staphylococcus aureus Clinical Isolates Causing Hospital-acquired Pneumonia (2013-2014) (2015) (0)
662: FREQUENCY AND ANTIMICROBIAL SUSCEPTIBILITY OF BACTERIA FROM VENTILATOR-ASSOCIATED PNEUMONIA (2019) (0)
A Review of Doripenem for the Treatment of Serious Bacterial Infections (2010) (0)
P1671 Antimicrobial activity of Ceftazidime and Piperacillin-Tazobactam tested in combination with a potentiator molecule (SPR741) against Enterobacteriaceae causing urinary-tract infections (2018) (0)
665. In vitro Activity of Omadacycline Against Recent (2018) Bacterial Pathogens from the United States and Europe Obtained from Skin and Skin Structure, Respiratory, and Urinary Tract Infections (2019) (0)
P65 Daptomycin activity when tested against uncommonly isolated streptococcal species and three other Gram-positive species groups (2013) (0)
Contemporary Analysis of Oritavancin in vitro Activity Against Staphylococcus aureus Responsible for Invasive Community- and Hospital-associated Infections among Patients in the USA (2013-2014) (2015) (0)
701. Comparison of MIC Results for Gepotidacin by Agar Dilution and Broth Microdilution Methods (2019) (0)
Distributions and Annual Changes of Streptococcus pneumoniae Serotypes Causing Infections in Adult Patients: Eight Years of US Surveillance (2009–2016) (2017) (0)
P64 Ceftaroline activity against common bacterial pathogens causing skin and soft tissue infections in the Asia-Pacific region and South Africa (2013) (0)
475Telavancin (TLV) In vitro Activity Tested Against a USA Collection of Methicillin-resistant Staphylococcus aureus (MRSA), Including a Multidrug-resistant (MDR) Subset (2011-2013) (2014) (0)
Tigecycline Activity Tested against Resistant Surveillance Subsets of Clinical Bacteria Collected Worldwide (2011) (2012) (0)
1598. Antimicrobial Activity of the Novel β-Lactam Enhancer Combination Cefepime–Zidebactam (WCK-5222) Tested Against Gram-Negative Bacteria Isolated in United States Medical Centers from Patients with Bloodstream Infections (2019) (0)
Ceftazidime-Avibactam Activity when Tested against Gram-Negative Bacteria Isolated from Patients With Pneumonia, Including Ventilator-Associated Pneumonia (VAP), Hospitalized in United States Medical Centers (2011-2015). (2016) (0)
Activity of Dalbavancin against Staphylococci and Streptococci Isolated from United States and European Patients with Blood, Respiratory, and Skin and Soft Tissue Infections (2004) (0)
Antimicrobial Activity of Ceftazidime-Avibactam and Comparator Agents Tested against Enterobacteriaceae and Pseudomonas aeruginosa from United States (US) Medical Centers Stratified by Infection Type (2015–2016) (2017) (0)
Sustained In Vitro Activity of Linezolid and Evolving Resistance Mechanisms: Summary of the Zyvox® Annual Appraisal of Potency and Spectrum Program for 2016 (2017) (0)
Molecular Characterization of Fluoroquinolone Resistance Mechanisms in Isolates from the Delafloxacin Acute Bacterial Skin and Skin Structure Infections Clinical Trials (2017) (0)
1000. Antimicrobial Susceptibility of Gram-Positive Bacteria Isolated From Patients Hospitalized With Bacteremia in United States and European Medical Centers: Results From the International Dalbavancin Evaluation of Activity (IDEA) Program (2018) (0)
1047. Global Surveillance: Susceptibility of Ceftolozane–Tazobactam Against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa Isolates Collected From Bloodstream Infections in the United States From 2015 to 2017 (2018) (0)
Evaluation of In Vitro Activity of Ceftaroline Tested against Streptococcus pneumoniae Isolates from United States Hospitals: Results from 7 Years of the AWARE Surveillance Program (2010–2016) (2017) (0)
Evaluation of the I n Vitro Activity of Ceftaroline Tested Against Clinical Bacterial Isolates from USA Hospitals: Results from 5 Years of the AWARE Surveillance Program (2011-2015) (2016) (0)
1590. Updated Aminoglycoside (AG) MIC Breakpoints (BP) to Minimize Adverse Events and Improve Outcome: Impact on Susceptibility (S) Rates (2019) (0)
Tight Binding ofClarithromycin, Its14-(R)-Hydroxy Metabolite, andErythromycin toHelicobacter pylori Ribosomes (1994) (0)
Antimicrobial Activity of Ceftaroline and Comparator Agents tested against Bacterial Organisms Causing Bacteremia in Patients with Skin and Skin Structure Infections (SSSI) in United States (USA) Medical Centers (2008-2014) (2015) (0)
P67 Activity of ceftaroline tested against recent (2011) respiratory tract infection pathogens from the Asia Pacific region and South Africa (2013) (0)
Antimicrobial Activity of Dalbavancin and Comparator Agents Tested against Gram-Positive Clinical Isolates Causing Bone and Joint Infections in United States (US) Medical Centers (2011–2016) (2017) (0)
729Activity of Ceftaroline and Comparator Agents Tested against Staphylococcus aureus from Patients with Bacteremia in United States (USA) Medical Centers (2009-2013) (2014) (0)
In Vitro Activity of KPI-10 Tested Against a Global Collection of Acinetobacter spp. Including Multi-Drug Resistant (MDR) Strains (2012) (0)
Antimicrobial activity of ceftobiprole versus other currently marketed cephalosporins and beta-lactams when tested against contemporary Gram-positive and -negative organisms collected from Europe (2015) (2017) (0)
696: FREQUENCY OF OCCURRENCE AND ANTIMICROBIAL SUSCEPTIBILITY OF BACTERIA IN ICU PATIENTS WITH PNEUMONIA (2016) (0)
Activity of Ceftolozane-Tazobactam and Comparators When Tested against Bacterial Surveillance Isolates Collected from Pediatric Patients in the US during 2012–2016 as Part of a Global Surveillance Program (2017) (0)
Antimicrobial susceptibility patterns of community- and hospital-acquired methicillin-resistant Staphylococcus aureus from United States Hospitals: results from the AWARE Ceftaroline (2016) (0)
Ceftazidime-Avibactam Antimicrobial Activity and Spectrum when Tested Against Gram-negative Organisms from Pediatric Patients: Results from the INFORM Surveillance Program (USA, 2011-2015) (2016) (0)
Erratum: Molecular typing of Helicobacter pylori isolates from a multicenter U.S. clinical trial by ureC restriction fragment length polymorphism (Journal of Clinical Microbiology 35:2 (471)) (1998) (0)
P66 Antimicrobial activity of ceftazidime–avibactam tested against Pseudomonas aeruginosa from China (2009–2010) (2013) (0)
Analysis of MIC Relationship Between Tedizolid, Linezolid and Vancomycin Tested Against S. aureus and Enterococcal Clinical Isolates from USA and European Hospitals (2014 - 2015) (2016) (0)
Helicobacterpylori from Gastric Mucosal Biopsies and Clinical Isolates (0)
1436. Comparison of Ceftazidime–Avibactam, Ceftolozane–Tazobactam, Piperacillin–Tazobactam, and Meropenem Activities When Tested Against Gram-Negative Organisms Isolated From Complicated Urinary Tract Infections (2019) (0)
In vitro Activity of Tedizolid in Comparison With Other Oral and Intravenous Agents Against a USA Collection of Community-acquired Methicillin-resistant Staphylococcus aureus (2014 - 2015) (2016) (0)
Telavancin Activity Against a Global Collection of Staphylococcus aureus Clinical Isolates (2013–2015) (2017) (0)
P710 Baseline activity of ceftobiprole against methicillin-susceptible and -resistant staphylococcal clinical isolates from Europe collected in 2005–2006 (2007) (0)
Comparison of fetal bovine serum and colostrum-free bovine serum supplements of virus culture. (1993) (0)
P1672 Evaluation of synergistic effects of a potentiator molecule (SPR741) when tested in combination with a series of beta-lactam agents against a challenge set of Gram-negative pathogens (2018) (0)
1583. Eight Years of Sustained Potency and Activity of Oritavancin against Gram-Positive Isolates Causing Bacteremia and Endocarditis in the USA, Including Enterococcal Infections Requiring an Optimized Dosing Strategy for Daptomycin (2019) (0)
410Tracking Linezolid Antimicrobial Activity and Resistance in North America: Results from LEADER 2013 Program (2014) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Robert K. Flamm?

Robert K. Flamm is affiliated with the following schools:

Baylor College of Medicine

Robert K. Flamm's Academic­Influence.com Rankings

Why Is Robert K. Flamm Influential?

Robert K. Flamm's Published Works

Published Works

What Schools Are Affiliated With Robert K. Flamm?

Robert K. Flamm's AcademicInfluence.com Rankings